[{"id":"15523e72-2092-4615-84e9-c8dac7362a0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07484087","created_at":"2026-03-28T01:36:33.328Z","updated_at":"2026-03-28T01:36:33.328Z","phase":"","brief_title":"Ablation Compare With Surgery for Early Breast Cancer","source_id_and_acronym":"NCT07484087","lead_sponsor":"Peking University People's Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + AR positive + ER positive"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2026-03-19"},{"id":"343860fb-1c41-454c-a2e5-97b25f553d79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02954874","created_at":"2021-01-18T14:30:57.547Z","updated_at":"2025-02-25T16:44:03.478Z","phase":"Phase 3","brief_title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","source_id_and_acronym":"NCT02954874","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1155","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-06"},{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"fbf3716a-0c89-444d-8fe3-c713df6342b5","acronym":"RaPhLRR","url":"https://clinicaltrials.gov/study/NCT05467891","created_at":"2022-07-21T12:57:26.496Z","updated_at":"2025-02-25T15:54:32.807Z","phase":"Phase 2","brief_title":"Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05467891 - RaPhLRR","lead_sponsor":"Oana Danciu","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-01-31"},{"id":"895cc6e3-6ceb-4627-b2e2-941b32623452","acronym":"ADAPTcycle","url":"https://clinicaltrials.gov/study/NCT04055493","created_at":"2021-01-18T19:52:55.710Z","updated_at":"2025-02-25T15:43:39.169Z","phase":"Phase 3","brief_title":"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC","source_id_and_acronym":"NCT04055493 - ADAPTcycle","lead_sponsor":"West German Study Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1684","initiation":"Initiation: 07/02/2019","start_date":" 07/02/2019","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-01-14"},{"id":"79775896-981f-4795-860c-5b8a8ca129f9","acronym":"ADEPT","url":"https://clinicaltrials.gov/study/NCT04569747","created_at":"2021-01-18T21:49:27.045Z","updated_at":"2025-02-25T12:27:45.281Z","phase":"Phase 2","brief_title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","source_id_and_acronym":"NCT04569747 - ADEPT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 375","initiation":"Initiation: 01/11/2021","start_date":" 01/11/2021","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-10-01"},{"id":"cf8bf0b5-ca6f-4f6e-a44f-54ab88c53b60","acronym":"FACILE","url":"https://clinicaltrials.gov/study/NCT03944434","created_at":"2021-01-18T19:25:17.328Z","updated_at":"2025-02-25T15:43:30.551Z","phase":"Phase 2","brief_title":"FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT03944434 - FACILE","lead_sponsor":"Fondazione Sandro Pitigliani","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • anastrozole • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 12/27/2018","start_date":" 12/27/2018","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 11/27/2025","study_completion_date":" 11/27/2025","last_update_posted":"2024-09-25"}]